A Signal From CMS
When federal agencies double their workforce in a specific area, it signals a strategic priority. The Centers for Medicare and Medicaid Services' Innovation Center has announced it is on track to more than double the team focused on drug price reduction, a move that coincides with several active pilot programs targeting the persistently high cost of medications for federal health program enrollees.
The CMS Innovation Center, formally known as the Center for Medicare and Medicaid Innovation, was created by the Affordable Care Act with an explicit mandate to test new payment and delivery models. Over the past several years, drug pricing has become an increasingly central focus as policymakers and the public have demanded action on prescription costs that frequently exceed those paid in comparable countries by wide margins.
What the Expansion Is Targeting
The expanded team will develop and manage pilot models aimed at lowering drug costs across both Medicaid and Medicare, which covers roughly 65 million Americans aged 65 and older or with qualifying disabilities. The specific models under development are not yet publicly detailed, but CMMI has historically operated through randomized controlled trials of payment structures, coverage requirements, and prescribing incentives designed to generate evidence for broader policy adoption if they succeed.
Drug pricing is a particularly complex target for innovation because it involves multiple distinct markets — brand-name drugs, generics, biologics, and biosimilars — each with different competitive dynamics, patent protection regimes, and reimbursement structures. A pilot program that successfully reduces costs in one segment may have limited transferability to another, which is why scaling up dedicated staff to manage multiple simultaneous programs across different drug categories makes strategic sense.
The Policy Context
The CMMI expansion comes in the context of the Inflation Reduction Act's drug pricing provisions, which for the first time gave Medicare direct negotiating authority over certain high-cost drugs. The first wave of negotiated drug prices took effect in 2026, and the results have provided both evidence of what direct negotiation can achieve and political ammunition for extending the program's scope.
Expanding the innovation center's capacity allows the federal government to pursue drug cost reduction through multiple channels simultaneously: the legislative negotiation mechanism created by the IRA on one track, and pilot programs testing additional approaches — including site-of-care shifting for infused medications, reference pricing experiments, and formulary design incentives — on another.
Staffing and Expertise Requirements
More than doubling a specialized government team is not trivial. CMMI draws on career civil servants, agency detail rotations, and external experts from health economics, clinical pharmacology, actuarial science, and health services research. The drug pricing focus requires people who understand both the technical complexity of how drug prices are set in US markets and the regulatory and statutory constraints on what CMS can require of manufacturers and pharmacy benefit managers.
CMMI has historically addressed recruitment challenges partly through time-limited fellowships and rotational programs that bring in domain experts for defined periods, and the current expansion is likely to lean on similar mechanisms.
Industry Response and Implications
The pharmaceutical industry has responded cautiously to the CMMI expansion. Brand-name drug manufacturers are generally opposed to expanded government price-setting authority and have challenged various aspects of the IRA's negotiation provisions in court. The innovation center's pilot programs, however, operate with more flexibility than direct price negotiation — they can test voluntary models with provider and plan participation, potentially generating evidence that is harder to oppose than legislative mandates.
For patients and the health system broadly, the expansion represents a meaningful investment in the difficult, iterative work of understanding how to make drugs more affordable without compromising the incentives that drive pharmaceutical innovation. Pilot programs are inherently provisional and evidence-driven, positioning them as a complement to rather than a replacement for harder political fights over drug pricing legislation.
This article is based on reporting by endpoints.news. Read the original article.
